Full-Time

Field Director

Medical Science Liaisons

Updated on 8/1/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$223.5k - $302.4k/yr

+ Annual bonus + Stock-based long-term incentives

Orlando, FL, USA + 3 more

More locations: Charlotte, NC, USA | Columbia, SC, USA | Atlanta, GA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
CRM

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and four years of Medical Affairs experience, or a master's degree and eight years of Medical Affairs experience, or a bachelor's degree and ten years of Medical Affairs experience.
  • Four years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources.
Responsibilities
  • Provide strategic direction and oversight to the MSL team, ensuring alignment with Amgen's corporate goals and objectives.
  • Coach and develop MSLs by evaluating performance and providing constructive feedback to enhance individual and team effectiveness.
  • Foster a positive, collaborative work environment that promotes retention and engagement by recognizing and rewarding high performance, providing growth and development opportunities, and supporting work-life balance.
  • Identify ongoing training needs of the MSL team and collaborate with training partners to develop a plan and timeline.
  • Ensure the MSL team adheres to compliance standards and completes administrative responsibilities, including the customer relationship management system, expense reports, and training modules, in a timely manner.
  • Lead effectively through change to accelerate MSL progression and drive achievement of medical initiatives.
  • Partner with medical leadership to develop field medical strategy, tactics, and Scientific Engagement Plans, including ways to measure success.
  • Elevate field medical insights that may refine strategy and tactics.
  • Identify tools and resources needed to support Scientific Engagement Plans and champion their development with the medical leadership team.
  • Oversee peer-to-peer scientific engagement activities with opinion leaders, community healthcare providers, and Population Health Decision Makers.
  • Develop strategies for engagement and execution at key accounts in collaboration with internal stakeholders.
  • Guide the MSL team in educating and communicating clinical value, outcomes, and economic data to Population Health Decision Makers within Integrated Delivery Networks and other institutions.
  • Provide ongoing support and guidance to the MSL team to ensure they meet their goals and remain focused on impactful strategies and tactics.
  • Ensure that the MSL team understands the healthcare ecosystem and Amgen's business landscape, and guide them in overcoming obstacles, promoting innovation, and adapting to changes in the MSL role.
  • Represent the MSL team in interactions with senior leadership and clearly articulate the impact of the Field Medical team.
  • Collaborate with internal stakeholders to ensure the MSL team provides field observations and insights that inform Amgen strategies.
  • Support congress activities, ensuring alignment with overall strategy.
  • Participate in and lead project teams that support Field Medical strategies and tactics.
  • Model and ensure excellence in cross-functional collaboration between field medical and field commercial to provide a coordinated experience for external partners.
Desired Qualifications
  • Pharm.D., Ph.D., M.D. or D.O. (other doctoral degrees considered).
  • Seven years of industry experience in Scientific/Medical Affairs at a biotech or pharmaceutical company.
  • Seven or more years focused on clinical practice, clinical research, or medical research; medically related experience may include postdoctoral training such as residencies or fellowships.
  • Three or more years in a medical science liaison role at a biotech or pharmaceutical company and current experience in Scientific Affairs or Medical Affairs at a biotech or pharmaceutical company.
  • Three years of managerial experience directly managing people and/or experience leading teams, projects, programs or directing the allocation of resources.
  • Expertise in obesity and related conditions.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.